Background Thrombotic disease complicates severe SARS‐CoV‐2 infection and is
associated with increased morbidity and mortality. Various anticoagulation strategies have …

Abstract Background Coronavirus disease 2019 (COVID-19) is associated with a
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …

The coronavirus disease 2019 (COVID-19) shows high incidence of thromboembolic events
in humans. In the present study, we aimed to evaluate if anticoagulation prior to COVID-19 …

Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

Anticoagulant therapy is a cornerstone treatment for coronavirus disease 2019 (COVID-19)
due to the high rates of thromboembolic complications associated with this disease. We …

Introduction: COVID-19 induces a pro-thrombotic state as evidenced by microvascular
thrombi in the renal and pulmonary vasculature. Therapeutic anticoagulation in COVID-19 …

Background: The potential benefit of therapeutic-dose anticoagulation for critically ill patients
with coronavirus disease 2019 (COVID-19) is still controversial. Methods and Results: In the …

Shortly after the emergence of coronavirus disease 2019 (COVID-19) in late 2019, clinicians
rapidly recognized an apparent association between the disease and both arterial and …